AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
OPKO Health, Inc.
Video analysis: OPK
All videosNo video analysis for this stock yet. Request one from our team.
News: OPK
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
Analyzing HCA Healthcare (NYSE:HCA) & OPKO Health (NASDAQ:OPK)
HCA Healthcare (NYSE: HCA - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares HCA Healthcare
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.
Connor Clark & Lunn Investment Management Ltd. Invests $618,000 in OPKO Health, Inc. $OPK
Connor Clark and Lunn Investment Management Ltd. acquired a new stake in OPKO Health, Inc. (NASDAQ: OPK) in the undefined quarter, according to the company in its most recent filing with the SEC. The fund acquired 412,051 shares of the biotechnology company's stock, valued at approximately $618,000. Connor Clark and Lunn Investment Management
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
Is OPK Worth Buying as Valuation Meets Improving Business Trends?
OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
